Episoder
-
Jon Chee hosts Michael Chen, the Co-Founder and CEO of Nuclera, a biotech company that focuses on bringing rapid protein access to other labs.
Michael is a seasoned scientist and entrepreneur who brings a rich background and valuable insights to our podcast. Before co-founding Nuclera, Michael did extensive research as an undergrad student at both Georgia tech and Emory and eventually got his PhD in Chemistry from the University of Cambridge. He has also published nine scientific papers and worked with several leading scientists in their field. -
Part 1 of 2: Jon Chee hosts our latest guest, Michael Chen, the Co-Founder and CEO of Nuclera, a biotech company that focuses on bringing rapid protein access to other labs. Michael is a seasoned scientist and entrepreneur who brings his rich background and insights to our podcast.
Before becoming the Co-Founder of Nuclera, Michael did extensive research as an undergrad student at both Georgia tech and Emory and eventually got his Ph,D in Chemistry from the University of Cambridge. Having worked under some of the leading scientists in their field Michael also has 9 scientific publications to his name. His past experiences both at the lab bench and as a CEO make these episodes ones you don’t want to miss. -
Manglende episoder?
-
Part 4 of 4:
Jon Chee hosts our latest guest, Neela Patel, Chief Business Officer at Bonum Therapeutics who are developing protein therapeutics to be used to treat a wide range of diseases. Neela is a seasoned scientist and business development executive with over 30 years of leadership experience in drug discovery and development.
Before her time at Bonum Therapeutics Neela worked as the CBO at Good Therapeutics, a biotech company that develops cutting edge protein-based drugs. Her impressive career also includes pivotal roles at Seattle Genetics, AbbVie, Abbott, and Genentech. Her extensive experience as both a scientist and business person give her unique insights you won’t want to miss. -
Part 3 of 4:
Jon Chee hosts our latest guest, Neela Patel, Chief Business Officer at Bonum Therapeutics who are developing protein therapeutics to be used to treat a wide range of diseases. Neela is a seasoned scientist and business development executive with over 30 years of leadership experience in drug discovery and development.
Before her time at Bonum Therapeutics Neela worked as the CBO at Good Therapeutics, a biotech company that develops cutting edge protein-based drugs. Her impressive career also includes pivotal roles at Seattle Genetics, AbbVie, Abbott, and Genentech. Her extensive experience as both a scientist and business person give her unique insights you won’t want to miss. -
Part 2 of 4:
Jon Chee hosts our latest guest, Neela Patel, Chief Business Officer at Bonum Therapeutics who are developing protein therapeutics to be used to treat a wide range of diseases. Neela is a seasoned scientist and business development executive with over 30 years of leadership experience in drug discovery and development.
Before her time at Bonum Therapeutics Neela worked as the CBO at Good Therapeutics, a biotech company that develops cutting edge protein-based drugs. Her impressive career also includes pivotal roles at Seattle Genetics, AbbVie, Abbott, and Genentech. Her extensive experience as both a scientist and business person give her unique insights you won’t want to miss. -
The Biotech Startups Podcast is brought to you by Excedr. Excedr provides life science startups with equipment leases on founder-friendly terms to accelerate R&D and commercialization.
Know anyone that needs lab equipment? Join Excedr’s referral program: Give Your Friends $1,000, and Earn $1,000 for Each Qualified Referral 💸.
Get your unique referral link by going to: refer.excedr.com/ZTHETY. -
Jon Chee hosts our latest guest, eMalick Njie, CEO of Ecotone AI, a healthcare company that is using AI to find cures for inherited diseases. eMalick is an experienced scientist and entrepreneur who has focused on blending his expertise in neuroscience with his knowledge of AI.
In addition to founding two AI companies, Ecotone and Genetic Intelligence, eMalick received his PhD in Neurobiology and Neuroscience from the University of Florida. His extensive and diverse experience from being a postdoctoral fellow at Columbia university to being the CEO of the AI thinktank NeuroStorm makes our conversation with him one you won’t want to miss. -
Part 3 of 4: Jon Chee hosts our latest guest, eMalick Njie, CEO of Ecotone AI, a healthcare company that is using AI to find cures for inherited diseases. eMalick is an experienced scientist and entrepreneur who has focused on blending his expertise in neuroscience with his knowledge of AI.
In addition to founding two AI companies, Ecotone and Genetic Intelligence, eMalick received his PhD in Neurobiology and Neuroscience from the University of Florida. His extensive and diverse experience from being a postdoctoral fellow at Columbia university to being the CEO of the AI thinktank NeuroStorm makes our conversation with him one you won’t want to miss. -
Part 2 of 4: Jon Chee hosts our latest guest, eMalick Njie, CEO of Ecotone AI, a healthcare company that is using AI to find cures for inherited diseases. eMalick is an experienced scientist and entrepreneur who has focused on blending his expertise in neuroscience with his knowledge of AI.
In addition to founding two AI companies, Ecotone and Genetic Intelligence, eMalick received his PhD in Neurobiology and Neuroscience from the University of Florida. His extensive and diverse experience from being a postdoctoral fellow at Columbia university to being the CEO of the AI thinktank NeuroStorm makes our conversation with him one you won’t want to miss. -
Part 1 of 4: Jon Chee hosts our latest guest, eMalick Njie, CEO of Ecotone AI, a company that is looking to use AI to find cures for rare inherited diseases. eMalick is an experienced scientist and entrepreneur who has focused on blending his expertise in neuroscience with his knowledge of AI.
In addition to founding two AI companies, Ecotone and Genetic Intelligence, eMalick received his PhD in Neurobiology and Neuroscience from the University of Florida. His extensive and diverse experience from being a postdoctoral fellow at Columbia university to being the CEO of the AI thinktank NeuroStorm makes our conversation with him one you won’t want to miss. -
Jon Chee hosts our latest guest, Barbara Alcaraz Silva, the Executive Director of Early Stage Life Sciences and Healthcare, Startup Banking at J.P. Morgan. Barbara brings a wealth of experience as a former researcher, entrepreneur, and industry veteran. She has worked extensively with startups and early-stage ventures. Her scientific background is in Telomeres and DNA Repair research.
Prior to her role at J.P. Morgan, Barbara advised biotech and medtech companies at Manos Accelerator, served as a Senior Investment Fellow at Life Science Angels, and co-founded BioChron, an AI-driven biological aging tracking company. Her unique combination of scientific knowledge, business acumen, and investment/finance expertise makes her an invaluable resource for founders in the biotech space. -
Part 3 of 4.
My guest for this week’s episode is Barbara Alcaraz Silva, Executive Director of Early Stage Life Sciences and Healthcare, Startup Banking at J.P. Morgan. Barbara is a former researcher and entrepreneur, and an accomplished industry veteran. Her career has revolved around startups and early-stage ventures. As a graduate student, she focused on Telomeres and DNA Repair.
Before joining J.P. Morgan, Barbara was an advisor for biotech and medtech companies at the Manos Accelerator, where she provided mentorship in business development, fundraising, and other key areas. She also served as a Senior Investment Fellow at Life Science Angels, where she invested in emerging biotechs and managed investor relationships. Additionally, Barbara co-founded BioChron, a company that leveraged AI and machine learning to track biological aging. -
Part 2 of 4.
My guest for this week’s episode is Barbara Alcaraz Silva, Executive Director of Early Stage Life Sciences and Healthcare, Startup Banking at J.P. Morgan. She is also a former scientist-entrepreneur whose graduate studies focused on Telomeres and DNA Repair. Barbara has worked with many startups, including co-founding her own company, BioChron. While at the Manos Accelerator, she worked as an advisor for Biotech and Medtech companies, providing mentorship in business, fundraising, and capital, and offering guidance to startup companies. Additionally, Barbara worked as a Senior Investment Fellow at Life Science Angels, investing in up-and-coming biotechs and managing investor relationships. -
Part 1 of 4.
My guest for this week’s episode is Barbara Alcaraz Silva, Executive Director of Early Stage Life Sciences and Healthcare, Startup Banking at J.P. Morgan. She is also a former scientist-entrepreneur whose graduate studies focused on Telomeres and DNA Repair. Barbara has worked with many startups, including co-founding her own company, BioChron. While at the Manos Accelerator, she worked as an advisor for Biotech and Medtech companies, providing mentorship in business, fundraising, and capital, and offering guidance to startup companies. Additionally, Barbara worked as a Senior Investment Fellow at Life Science Angels, investing in up-and-coming biotechs and managing investor relationships. -
Part 4 of 4.
My guest for this week’s episode is Derek Hennecke, a veteran biotech entrepreneur and board member with over 30 years of experience in the CDMO industry, whose mission is to support the biotech revolution and create value for patients, customers, and investors.
In addition to his Board work, Derek previously held leadership positions at DSM and was the Founder and CEO of Xcelience, a Florida-based CDMO specializing in preformulation, micronization, analytical services, formulation development, cGMP manufacturing, and more. Derek eventually sold Xcelience to Capsugel (now Lonza) in 2016.
His extensive pharma and cell therapy expertise makes for an insightful conversation that founders can learn from. -
Part 3 of 4.
My guest for this week’s episode is Derek Hennecke, a veteran biotech entrepreneur and board member with over 30 years of experience in the CDMO industry, whose mission is to support the biotech revolution and create value for patients, customers, and investors.
In addition to his Board work, Derek previously held leadership positions at DSM and was the Founder and CEO of Xcelience, which he eventually sold to Capsugel Lonza in 2016. Xcelience was a Florida-based CDMO specializing in preformulation, micronization, analytical services, formulation development, cGMP manufacturing, and more. His extensive pharma and cell therapy expertise makes for an insightful conversation that founders can learn from. -
Part 2 of 4.
My guest for this week’s episode is Derek Hennecke, a veteran biotech entrepreneur and board member with over 30 years of experience in the CDMO industry, whose mission is to support the biotech revolution and create value for patients, customers, and investors.
In addition to his Board work, Derek previously held leadership positions at DSM and was the Founder and CEO of Xcelience, which he eventually sold to Capsugel Lonza in 2016. Xcelience was a Florida-based CDMO that specialized in preformulation, micronization, analytical services, formulation development, cGMP manufacturing, and more. His extensive expertise in pharma and cell therapy makes for an insightful conversation that founders can learn from. -
Part 1 of 4.
My guest for this week’s episode is Derek Hennecke, a veteran biotech entrepreneur and board member with over 30 years of experience in the CDMO industry, whose mission is to support the biotech revolution and create value for patients, customers, and investors.
In addition to his Board work, Derek previously held leadership positions at DSM and was the Founder and CEO of Xcelience, which he eventually sold to Capsugel Lonza in 2016. Xcelience was a Florida-based CDMO that specialized in preformulation, micronization, analytical services, formulation development, cGMP manufacturing, and more. His extensive expertise in pharma and cell therapy makes for an insightful conversation that founders can learn from. -
Part 4 of 4.
My guest for this week’s episode is Doug Drysdale, CEO at Cybin. Cybin is a clinical-stage biopharma company on a mission to create safe and effective psychedelic-based therapeutics.
Doug is an experienced investor, Corporate Director and CEO, who has chaired the Board of a NASDAQ-listed company and, as a CEO for the past 12 years, has built and turned around 3 pharma companies. During his 30+ years of experience in the healthcare sector, he has formed cohesive management teams, recruited board members, completed 16 corporate acquisitions across three continents and has raised and invested around $4 billion of both public and private capital. -
Part 3 of 4.
My guest for this week’s episode is Doug Drysdale, CEO at Cybin. Cybin is a clinical-stage biopharma company on a mission to create safe and effective psychedelic-based therapeutics.
Doug is an experienced investor, Corporate Director and CEO, who has chaired the Board of a NASDAQ-listed company and, as a CEO for the past 12 years, has built and turned around 3 pharma companies. During his 30+ years of experience in the healthcare sector, he has formed cohesive management teams, recruited board members, completed 16 corporate acquisitions across three continents and has raised and invested around $4 billion of both public and private capital. - Vis mere
